Enhanced delivery of IL-1 receptor antagonist to the central nervous system as a novel anti-Transferrin receptor-IL-1RA fusion reverses neuropathic mechanical hypersensitivity

Pain

Volumn 158, Issue 4, 2017, Pages 660-668

  Webster, Carl I ^a   Hatcher, Jon ^b   Burrell, Matthew ^a   Thom, George ^a   Thornton, Peter ^b   Gurrell, Ian ^b   Chessell, Iain ^b  

^a Antibody Discovery and Protein Engineering   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Analgesic; Antibody; Blood brain barrier; Interleukin 1; Neuropathic pain

Indexed keywords

ANAKINRA; COMPLEMENTARY DNA; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRANSFERRIN RECEPTOR; ANTIBODY; IL1RN PROTEIN, HUMAN; TFRC PROTEIN, MOUSE;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG TRANSPORT; HUMAN; MECHANICAL HYPERALGESIA; MOUSE; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT; SCIATIC NERVE; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; FEMALE; HYPERALGESIA; IMMUNOLOGY; MALE; NIH 3T3 CELL LINE; PHYSIOLOGY; SCIATICA; TIME FACTOR;

ANIMALS; ANTIBODIES; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYPERALGESIA; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MICE; MICE, INBRED C57BL; NIH 3T3 CELLS; RECEPTORS, TRANSFERRIN; RECOMBINANT FUSION PROTEINS; SCIATICA; TIME FACTORS;

EID: 85018177674     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000000810     Document Type: Article

References (42)

1. Alexander GM, van Rijn MA, van Hilten JJ, Perreault MJ, Schwartzman RJ. Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. PAIN 2005;116:213-19.
2. Apkarian AV, Lavarello S, Randolf A, Berra HH, Chialvo DR, Besedovsky HO, del Rey A. Expression of IL-1beta in supraspinal brain regions in rats with neuropathic pain. Neurosci Lett 2006;407:176-81.
3. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010;10: 345-52.
4. Boado RJ, Zhang Y, Wang Y, Pardridge WM. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotech Bioeng 2009;102: 1251-8.
5. Burgess G, Williams D. The discovery and development of analgesics: new mechanisms, new modalities. J Clin Invest 2010;120:3753-9.
6. Carter DB, Deibel MRJ, Dunn CJ, Tomich CS, Laborde AL, Slightom JL, Berger AE, Bienkowski MJ, Sun FF, McEwan RN. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990;344:633-8.
7. Chessell IP, Dudley A, Billinton A. Biologics: The next generation of analgesic drugs? Drug Discov Today 2012;17:875-9.
8. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, Peck WL, Grahames CBA, Casula MA, Yiangou Y, Birch R, Anand P, Buell GN. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. PAIN 2005;114:386-96.
9. Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji RN, Meilandt WJ, Solanoy H, Tong RK, Hoyte K, Luk W, Lu Y, Gadkar K, Prabhu S, Ordonia BA, Nguyen Q, Lin Y, Lin Z, Balazs M, Scearce-Levie K, Ernst JA, Dennis MS, Watts RJ. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med 2013;5:183ra57.
10. Daramola O, Stevenson J, Dean G, Hatton D, Pettman G, Holmes W, Field R. A high-yielding CHO transient system: coexpression of genes encoding EBNA-1 and GS enhances transient protein expression. Biotechnol Prog 2014;30:132-41.
11. del Rey A, Apkarian AV, Martina M, Besedovsky HO. Chronic neuropathic pain-like behavior and brain-borne IL-1beta. Ann N Y Acad Sci 2012; 1262:101-7.
12. del Rey A, Yau H, Randolf A, Centeno MV, Wildmann J, Martina M, Besedovsky HO, Apkarian AV. Chronic neuropathic pain-like behavior correlates with IL-1beta expression and disrupts cytokine interactions in the hippocampus. PAIN 2011;152:2827-35.
13. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87: 2095-147.
14. Ferreira SH, Lorenzetti BB, Bristow AF, Poole S. Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 1988;334:698-700.
15. Fiorentino PM, Tallents RH, Miller JH, Brouxhon SM, OBanion MK, Puzas JE, Kyrkanides S. Spinal interleukin-1beta in a mouse model of arthritis and joint pain. Arthritis Rheum 2008;58:3100-9.
16. Gabay E, Wolf G, Shavit Y, Yirmiya R, Tal M. Chronic blockade of interleukin-1 (IL-1) prevents and attenuates neuropathic pain behavior and spontaneous ectopic neuronal activity following nerve injury. Eur J Pain 2011;15:242-8.
17. Kawasaki Y, Zhang L, Cheng J, Ji R. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-Alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci 2008;28: 5189-94.
18. Kissel K, Hamm S, Schulz M, Vecchi A, Garlanda C, Engelhardt B. Immunohistochemical localization of the murine transferrin receptor (TfR) on blood-Tissue barriers using a novel anti-TfR monoclonal antibody. Histochem Cell Biol 1998;110:63-72.
19. Lee HJ, Engelhardt B, Lesley J, Bickel U, Pardridge WM. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through bloodbrain barrier in mouse. J Pharmacol Exp Ther 2000;292:1048-52.
20. Lee HJ, Boado RJ, Braasch DA, Corey DR, Pardridge WM. Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntingtons disease with an antisense radiopharmaceutical and drugtargeting technology. J Nucl Med 2002;43:948-56.
21. Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab 2002;22:223-31.
22. Lee H, Lee K, Son S, Hwang S, Cho H. Temporal expression of cytokines and their receptors mRNAs in a neuropathic pain model. Neuroreport 2004;15:2807-11.
23. Moos T, Morgan EH. Evidence for low molecular weight, non-Transferrinbound iron in rat brain and cerebrospinal fluid. J Neurosci Res 1998;54: 486-94.
24. Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, Rueger P, Stracke J, Lau W, Tissot A, Loetscher H, Ghosh A, Freskgard PO. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 2014;81:49-60.
25. Oganesyan V, Gao C, Shirinian L, Wu H, DallAcqua WF. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallog D Biol Crystallogr 2008;64:700-4.
26. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci 1995;4: 2411-23.
27. Persic L, Roberts A, Wilton J, Cattaneo A, Bradbury A, Hoogenboom HR. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 1997; 187:9-18.
28. Pettersson LME, Geremia NM, Ying Z, Verge VMK. Injury-Associated PACAP expression in rat sensory and motor neurons is induced by endogenous BDNF. PLoS One 2014;9:e100730.
29. Randall LO, Selitto JJ. Amethod formeasurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957;111:409-19.
30. Reeve AJ, Patel S, Fox A, Walker K, Urban L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. Eur J Pain 2000;4:247-57.
31. Ren K, Torres R. Role of interleukin-1beta during pain and inflammation. Brain Res Rev 2009;60:57-64.
32. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV, Woolf CJ. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001;410:471-5.
33. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. PAIN 1990;43: 205-18.
34. Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM. Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci U S A 2001;98:12754-9.
35. Uceyler N, Tscharke A, Sommer C. Early cytokine expression in mouse sciatic nerve after chronic constriction nerve injury depends on calpain. Brain Behav Immun 2007;21:553-60.
36. Wang X, Wang C, Zeng J, Xu X, Hwang PYK, Yee W, Ng Y, Wang S.Gene transfer to dorsal root ganglia by intrathecal injection: effects on regeneration of peripheral nerves. Mol Ther 2005;12:314-20.
37. Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, Pairaudeau G, Pennie WD, Pickett SD, Wang J, Wallace O, Weir A. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov 2015;14:475-86.
38. Watson PM, Paterson JC, Thom G, Ginman U, Lundquist S, Webster CI. Modelling the endothelial blood-CNS barriers: A method for the production of robust in vitro models of the rat blood-brain barrier and blood-spinal cord barrier. BMC Neurosci 2013;14:59.
39. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, Dennis MS. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Trans Med 2011;3:84ra44.
40. Zhang R, Li A, Liu B, Wang L, Ren K, Zhang H, Berman BM, Lao L. IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1 subunit in rats. PAIN 2008; 135:232-9.
41. Zhang Y, Pardridge WM. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J Pharmacol Exp Ther 2005;313:1075-81.
42. Zhu C, Zhang Y, Pardridge WM. Widespread expression of an exogenous gene in the eye after intravenous administration. Invest Ophthalmol Vis Sci 2002;43:3075-80.